Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma

Documenti analoghi

• Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
  di: Field-Smith, Antonia, et al.
  Pubblicazione: (2006)
• Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia
  di: Raedler, Lisa A.
  Pubblicazione: (2015)
• Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
  di: Raedler, Lisa A.
  Pubblicazione: (2015)
• Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
  di: Raedler, Lisa A.
  Pubblicazione: (2016)
• Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
  di: Fala, Loretta
  Pubblicazione: (2015)